generalized

Duloxetine 是一种 5 羟色胺-去甲肾上腺素重吸收 (serotonin-norepinephrine reuptake) 抑制剂，Ki=4.6 nM，可作用于广泛性焦虑症的研究。

Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) 是一种 5-羟色胺-去甲肾上腺素重吸收 (serotonin-norepinephrine reuptake) 抑制剂 (SNRI)，Ki=4.6 nM，可用于广泛性焦虑症的研究。

Benin (Butocine) 是细胞生长抑制剂，可用于研究广义的乳腺癌。

Dulozafone (F1933) 具有抗在脑杏仁核点燃模型中显示出抗惊厥活性，可保护完全点燃的大鼠免受全身性癫痫发作。

Topiramate (RWJ 17021) 是一种GluR5受体拮抗剂，可通过增强GABAergic 活性，抑制kainate AMPA 受体，抑制钠和钙通道的电压敏感，增加钾电导并抑制碳酸酐酶来产生抗癫痫作用，用于治疗部分性和全身性癫痫发作。

Beclamide (Chlorakon) 是一种抗惊厥药，具有抗惊厥作用。

L-Pipecolic acid (L-Homoproline) 是赖氨酸的分解产物，它能在患有常染色体遗传性疾病的婴儿体液中积累，比如新生儿肾上腺机能障碍， Zellweger 综合征等。

Harmaline hydrochloride (Harmidine hydrochloride) 是一种荧光吲哚生物碱，来自 harmala 生物碱和 β-咔啉。它是 harmine 的部分氢化形式。 Harmaline 通过诱导下橄榄神经元的节律性放电在正常大鼠中产生全身性震颤。

N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea 是一种抗惊厥剂，对广泛强直和部分性发作挛性具有潜在的研究价值。

Duloxetine D3 hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).Duloxetine D3 hydrochloride ((S)-Duloxetine D3 hydrochloride) i

Apinocaltamide(ACT-709478)是一种可口服和选择性的T型Ca 2+ 通道 (T-type calcium channel) 阻滞剂，具有可透过血脑屏障（BBB）的特性，对Cav3.1, Cav3.2和 Cav3.3的IC50=6.4~18nM，常用于癫痫的研究。

Troriluzole 是一种具有口服活性谷氨酸调节剂，具有抗癌活性。Troriluzole 可提高位于神经胶质细胞的兴奋性氨基酸转运体的表达，可用于研究脊髓小脑性共济失调、阿尔茨海默病和广泛性焦虑症 (GAD) 。

Siramesine Fumarate, a sigma receptor agonist, is used potentially for the treatment of generalized anxiety disorder.

D3017 是 D2624 的主要酒精代谢产物，具有口服活性和抗惊厥特性。在小鼠中，其ED50值为 1.5 mg kg，可用于研究严重的全身性强直阵挛发作（大发作）和部分性复杂癫痫。

SCH-23390 是一种针对多巴胺 D1 样受体的拮抗剂，具有D1 和 D5 受体亚型的Ki值分别为0.2 nM 和0.3 nM。它能够缩短可卡因诱导下大鼠杠杆按压行为的潜伏期。SCH-23390 还能消除由化学惊厥剂毛果芸香碱和梭曼引发的全身性癫痫发作，广泛用于研究多巴胺系统的神经疾病。

Opipramol (Ensidon) 是一种非典型三环类抗抑郁剂 (TCA)，主要作为 sigma (σ) 受体激动剂，与 sigma 识别位点高效结合，Ki值为50 nM。Opipramol 可用于广泛性焦虑症（GAD）的研究。

Buspirone hydrochloride (Buspar) 是一种 5HT(1A) 受体激动剂，可用于研究广泛性焦虑症。

M-5011 is a non-steroidal anti-inflammatory drug and immunomodulator potentially for the treatment of inflammation and pain. M-5011 had an effective antinociceptive activity (ED50 value) of 0.63 mg kg. M-5011 partially inhibits the generalized bone loss a

Cognac oil, predominantly derived from wine lees, exhibits distinctive fatty acid compositions, characterized by high proportions of Palmitic acid (59.26%), Linoleic acid (11.92%), Myristic acid (8.97%), and Oleic acid (8.3%) among other fatty acids. Notably, the application of Cognac oil enhances the permeability of Rhodamine 6G (R6G) across various membranes, resulting in a generalized increase in permeation.

Piragliatin, also known as RO4389620, is a glucokinase activator. Piragliatin greatly enhances glucose-induced pancreatic islet respiration and insulin release. Piragliatin lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus. Piragliatin has an acute glucose-lowering action in patients with mild type 2 diabetes, mainly mediated through a generalized enhancement of β-cell function and through fasting restricted changes in glucose turnover.

GYKI 52466 is an allosteric AMPA receptor antagonist. It selectively inhibits AMPA-induced inward currents (IC50 = 7.5 µM) over NMDA- or GABA-induced inward currents in primary rat hippocampal neurons at 50 µM but also inhibits kainate-induced inward currents in the same cells (IC50 = 11 µM).2 GYKI 52466 (10 µM) reduces the amplitude of spontaneous excitatory postsynaptic currents (EPSCs) in the same cells. It increases the latency to seizure onset and reduces mortality in a rat model of generalized tonic-clonic seizures induced by 4-aminopyridine (4-AP) when administered at doses of 25 and 50 mg kg. GYKI 52466 (30 mg kg) prevents neuronal damage in the CA1 region of the hippocampus in a rat model of global ischemia-reperfusion injury induced by four-vessel occlusion.

AZD-6280 是一种新型的亚型选择性 GABAAα2 3 受体阳性调节剂，用于治疗广泛性焦虑症。

NaV1.2 1.6 channel blocker-1 是一种有效的 NaV1.2 1.6 channel 阻滞剂，对 rNaV1.6 和 hNaV1.2 有抑制作用。NaV1.2 1.6 channel blocker-1 可用于研究全身性癫痫和运动障碍。

Risankizumab (BI 655066) 是一种人源化靶向 IL-23 p19 亚基的 IgG 单克隆抗体(Kd <10 pM)。 Risankizumab 能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生，IC50 值为 2 pM。Risankizumab 可用于预防和治疗如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病类的免疫性和炎症性疾病。